Novaccess Global Inc. · OTC:XSNX
Novaccess Global — Investor Presentation (April 2021)
25 slides from Novaccess Global's investor presentation, April 2021
Slide 1: NovAccess Global
Confidential and Proprietary. Copyright 2020 by NovAccess Global, Inc. All Rights Reserved. Market Symbol XSNX
Slide 2: Forward-Looking Statements
Forward-Looking Statements This information package contains forward-looking statements, which includes forecasts and timelines. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipate
Slide 3: About Us
About Us NovAccess Global is a novel cancer therapeutics company that capitalizes on the 3rd generation immunotherapy developed at Cedars-Sinai Medical Center to treat brain cancer A publicly-traded, SEC-registered biotech company An expert scientific and managerial team focused on acceleration of b
Slide 4: Our Focused Mission
Our Focused Mission Acquisition of cutting-edge assets in oncology and neurological disease Utilization of our expert team’s visionary collaboration Enhance and accelerate bringing assets to market Addition of unique Artificial Intelligence AI will allow us to: • Provide novel diagnostics with real
Slide 5: History of NovAccess Global
History of NovAccess Global Studies Studies Commence Conclude • TLR-AD1 Patent Issued #1 Biotech Patents • StemVax Therapeutics Company in Filed LLC Formed Pasadena, CA Pre-Clinical • 100% Acquired by Patent 20% Acquired by Innovest Global Inc. Studies, Animal Reviewed Innovest Global Inc. • Purchas
Slide 6: Dwain Irvin, Chief Executive Officer
Dwain Irvin, Chief Executive Officer Educational Background PhD, UCLA School of Medicine, Molecular & Medical Pharmacology, 2002 MPH, UCLA School of Public Health, Environmental Sciences, 1995 BA, The Johns Hopkins University, 1988 Asst. Professor, Research Scientist, Cedars-Sinai Medical Center, Ne
Slide 7: Dwain Irvin, Chief Executive Officer
Dwain Irvin, Chief Executive Officer Ventures Co-Founder of 2 start-up companies in Biotechnology and Stem Cell Biology. • Founder, Chief Scientific Officer, StemVax Inc. (Immunotherapy for Brain Cancer) 2015 - present • 2 patents in brain cancer therapeutics, (Glioblastoma Multiforme) • Developed a
Slide 8: Our Team
Our Team Each Contributor, an Expert in their Field – Highly Focused, yet Adaptable Management Dwain Irvin PHD, MPH Michael Yukich Chief Executive Officer Chief Financial Officer Scientific Advisory Board Renard Currie MBA Laina King PHD Lachlan Thompson PHD Christopher Wheeler PHD Andrew Norris PHD
Slide 9: Strategic Acquisition & Milestones
Strategic Acquisition & Milestones Novel Therapy to Treat Brain Cancer Immunotherapy - Glioblastoma Multiforme Q3 2020 Q1 2021 Q4 COMPLETED Acquire File pre-IND Confidential 2020 Market Symbol XSNX
Slide 10: Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) • More than 18,000 brain tumors are diagnosed each year in the United States • GBM is the most common primary brain tumor in adult • Five-year survival rates are less than 5% for GBM • Despite advances in Radiation and Chemotherapy no change in GBM patient survival in o
Slide 11: Glioblastoma Multiforme (GBM) Market Analysis
Glioblastoma Multiforme (GBM) Market Analysis • 2018, Global, $700 Million Market size, CAGR 9.3% (GlobalData Inc. 2019) • 2026, US, 2.9 Billion Market Size (GlobalData Inc. 2019) • No current immunotherapy for brain tumors • Expect 5% market penetration within first 5 years in market Confidential 2
Slide 12: Glioblastoma Multiforme (GBM): Problem and Solution
Glioblastoma Multiforme (GBM) Problem: • Standard of Care: Surgical resection followed by radiation and chemotherapy • 15-month median survival • No Cures, additional GBM therapies needed Solution: • Immunotherapy: 3 Major Types 1. Administration of antigen-pulsed dendritic cell (DC) immunotherapy 2
Slide 13: Immunotherapy Against GBM
Immunotherapy Against GBM History of Technology • Licensed from Cedars-Sinai Medical Center, Department of Neurosurgery • Cedars-Sinai Medical Center ranked 8th in US; Neurosurgery Department ranked 12th in US (US World New and Reports, 2020) • NovAccess Global technology is 3rd Generation immunothe
Slide 14: NovAccess Immunotherapy Against GBM: Third Generation
NovAccess Immunotherapy Against GBM Third Generation Immunotherapy 3rd Generation 35% improvement over 1st generation in animals 1st and 2nd Generation Improves survival in GBM responders (Phase I, II) NOT a cure – Reduces chance of GBM recurrence Confidential 2020 Market Symbol XSNX
Slide 15: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy Tumor Blood TUMOR ANTIGEN CELLS ANTIGEN-PRESENTING CELLS (Dendritic Immune Cells) Neurosurgeon Isolates Tumor and Immune Cells - Sends to Lab Confidential 2020 Market Symbol XSNX
Slide 16: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy ANTIGEN-PRESENTING CELLS TUMOR ANTIGEN CELLS (Dendritic Immune Cells) Isolated Tumor and Immune Cell Groups Comingled Utilizing TLR-AD1 Technology Confidential 2020 Market Symbol XSNX
Slide 17: Brain Tumor Immunotherapy
Brain Tumor Immunotherapy • Giloma Tumor Cell Lysate • Freeze-Thaw Method Used to Activate Immune Response • ‘Intelligence-Briefed’ Immune Cells Introduced into Bloodstream • T-Cells Trained to Identify Tumor and Anti-Tumor Response Initiated TLR-AD1 GBM Vaccine Administered Confidential 2020 Market
Slide 18: Dendritic Cell Vaccine (1st Generation)
Dendritic Cell Vaccine (1st Generation) • Improves survival in responders (Phase I and II) • Not a cure - Reduces chance of GBM recurrence • Needs improvement-survival rates, outcomes Confidential 2020 Market Symbol XSNX
Slide 19: 1st Generation Vaccine-Bulk Tumor Lysate
1st Generation Vaccine-Bulk Tumor Lysate TTS (time from surgical resection immediately preceding vaccination to time of death) -Wheeler et al, 2008, Cancer Research Confidential 2020 Market Symbol XSNX
Slide 20: 2nd Generation Vaccine Common Antigens (ICT-107)
2nd Generation Vaccine 6 Common Antigens (ICT-107) ICT-107 - Targets Cancer Stem Cells Lead Indication in GBM Antigen Treats gp100 melanoma, brain MAGE-1 melanoma, brain, ovarian IL-13Ra2 brain, ovarian Her-2/neu breast, ovarian AIM-2 breast, colon, brain Trp-2 melanoma, brain Confidential 2020 Mark
Slide 21: 3rd Generation Vaccine
3rd Generation Vaccine • 2nd Generation Vaccine Phase II data not encouraging • Antigen specific or antigens derived from bulk lysate combined with Toll-like receptor (TLR) adjuvants • Pre-clinical mouse model data show significant improvements in survival and dendritic cell activation and function
Slide 22: 3rd Gen vs. 1st Gen
3rd Gen vs. 1st Gen Pre-Clinical (Animal Study) Kaplan-Mier Survival Analysis of Vaccinated Glioma Bearing Mice (Controls) Median Survival • 1st Gen: 60 days • 3rd Gen + TLR Combos: 81 days Confidential 2020 Market Symbol XSNX
Slide 23: Investment Highlights
Investment Highlights • NovAccess Global, Pre-IND stage biopharmaceutical company developing next-generation immunotherapy products to treat Brain Cancer • Personalized Immunotherapy • Lead Candidate, TLR-AD1, dendritic cell-based vaccine for the treatment of glioblastoma multiforme (“GBM”) • IP est
Slide 24: Investment Raise
Investment Raise $5 Million to $15 Million Capital to Support: • Pre-IND Filing • IND Filing • Phase I/II Clinical Trials ($5 million) or Phase IIa Clinical Trial ($15 million) Confidential 2020 Market Symbol XSNX
Slide 25: Thank You!
Thank You! Confidential 2020 Market Symbol XSNX
NovAccess Global — Investor Presentation (April 2021) on 6ix